Le Lézard
Classified in: Health, Science and technology
Subjects: NPT, PDT

Essent Biologics Introduces Human Demineralized Bone Matrix (DBM) Bioink For 3D Bioprinting And Tissue Engineering Research Applications


CENTENNIAL, Colo., Sept. 21, 2021 /PRNewswire/ -- Essent Biologicstm, a nonprofit biotechnology company, today announced the launch of its spectral demineralized bone matrix (DBM), first of its kind,human-derived DBM for 3D bioprinting and tissue engineering research applications.  Essent Biologics will provide an osteoconductive DBM powder with osteoinductive potential derived from adult human cortical bone.

The company's DBM powder is specifically formulated for bone tissue engineering research, complex in vitro bone models for drug discovery and other regenerative medicine research applications for musculoskeletal tissue. The product is an acid-extracted organic matrix from human bone and retains much of the components native to bone, such as calcium-based solids, inorganic phosphates and some trace of cell debris.

"We are excited to launch our first scaffold product for the regenerative medicine space," said Corey Stone,  President, Essent Biologics. "Our DBM will support research efforts for next generation bone therapeutics, produce validated utility, and demonstrate opportunities to enhance outcomes in bone repair."

DBM is a biomaterial used in bone defects with a long track record of clinical use in diverse forms. Essent Biologics' DBM for research use is the ideal particle size for extrusion 3D bioprinting at 125-355µ particle size, recovered and processed without the use of antibiotics or animal products and tested for sterility and residual moisture.

For additional information on the company's product pipeline, please visit essentbiologics.org/products/.

About Essent Biologics
Essent Biologics is setting a new standard in human-derived biomaterials and comprehensive data for research. The nonprofit biotechnology company provides low-passaged primary cells, research tissue and scaffold materials to advance regenerative medicine research from benchtop to bedside. Essent Biologics supplies products in small or large volumes and serves as a manufacturing partner by creating master cell banks and an inventory of custom products within a tailored specification. In order to ensure reliable product quality, safety and efficacy, all Essent Biologics products are developed using robust design control processes and produced under current Good Manufacturing Practices (cGMP). For more information, please visit essentbiologics.org.

SOURCE Essent Biologics


These press releases may also interest you

at 02:00
Amwins Global Risks is delighted to announce Classic Cars and Cotswolds, an auction to raise money for the Matthew Wilson Multiple Myeloma Fund at Blood Cancer UK. The online auction opens today and features Ferraris, Aston Martins, a Rolls Royce, a...

at 01:35
Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...

at 00:39
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly...

25 avr 2024
The report titled "Anti-Adhesion Products Market by Product Type (Natural Adhesion Barriers, Synthetic Adhesion Barriers), Product Form (Film Formulation, Gel Formulation, Liquid Formulation), Application, End-User - Global Forecast 2024-2030" is now...

25 avr 2024
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

25 avr 2024
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...



News published on and distributed by: